Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Sunil S. Patel"'
Autor:
Arshad M. Khanani, MD, MA, Sunil S. Patel, MD, PhD, Victor H. Gonzalez, MD, Suk J. Moon, MD, Glenn J. Jaffe, MD, John A. Wells, MD, Petra Kozma, MD, PhD, Pravin U. Dugel, MD, Raj K. Maturi, MD
Publikováno v:
Ophthalmology Science, Vol 1, Iss 3, Pp 100040- (2021)
Purpose: To evaluate the safety and preliminary efficacy of THR-687 in patients with center-involved diabetic macular edema (DME). Design: Phase 1, open-label, multicenter, 3 + 3 dose-escalation study with 3-month follow-up. Participants: Patients 18
Externí odkaz:
https://doaj.org/article/2a02a062908b428c989859c995417793
Autor:
Sunil S. Patel, David R. Lally, Jason Hsu, Charles C. Wykoff, David Eichenbaum, Jeffrey S. Heier, Glenn J. Jaffe, Keith Westby, Dhaval Desai, Liansheng Zhu, Arshad M. Khanani
Publikováno v:
Eye.
Autor:
Sunil S. Patel, David R. Lally, Jason Hsu, Charles C. Wykoff, David Eichenbaum, Jeffrey S. Heier, Glenn J. Jaffe, Keith Westby, Dhaval Desai, Liansheng Zhu, Arshad M. Khanani
Publikováno v:
Eye.
Background/Objectives To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course. Subjects/Methods This study was an
Autor:
John Randolph, Harvey Masonson, Brian C. Joondeph, Keith Westby, Joel A. Pearlman, Sunil S. Patel, K.A. Rezaei, Karl G. Csaky, Glenn J. Jaffe, Jordi Monés
Publikováno v:
Ophthalmology. 128:576-586
Purpose The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with
Autor:
Eleonora M. Lad, Majid Anderesi, Jeffrey S. Heier, Erin C. Henry, Spectri Study Investigators, Sarah Gray, Andrew J. Lotery, Dante J. Pieramici, Daniela Ferrara, Sunil S Patel, Sunil Gupta, Usha Chakravarthy, Elizabeth Tschosik, David Silverman, Robyn H. Guymer, Chroma
Publikováno v:
Ophthalmology Retina. 4:673-688
Purpose To assess visual function outcomes to 48 weeks in patients with bilateral geographic atrophy (GA) secondary to age-related macular degeneration included in 2 interventional clinical trials: relationship to baseline lesion size, outcomes by ba
Autor:
Robert Vitti, Friedrich Asmus, Karen W. Chu, Jeffrey S. Heier, Sunil S. Patel, Sergio Leal, David M. Brown, John W. Kitchens, Thomas Schmelter, Lorah Perlee, Charles C. Wykoff, Vladimir Son, Nadia K Waheed
Publikováno v:
Ophthalmology. 127:211-220
Purpose To compare the efficacy and safety of intravitreal aflibercept + anti–platelet-derived growth factor receptor β (PDGFRβ) combination with intravitreal aflibercept injection (IAI) monotherapy in patients with treatment-naive neovascular ag
Autor:
Glenn J. Jaffe, Keith Westby, Karl G. Csaky, Jordi Monés, Joel A. Pearlman, Sunil S. Patel, Brian C. Joondeph, John Randolph, Harvey Masonson, Kourous A. Rezaei
Publikováno v:
Ophthalmology. 128(12)
Autor:
Yichen Tan, Yu Fan, Matthew R. Hickey, Michael A. Schmidt, Christopher Wilbert, Darryl D. Dixon, Vidya Iyer, Fanfair Dayne Dustan, Benjamin M. Cohen, Matthew W. Haley, Jason M. Stevens, Miao Yu, Kenneth J. Fraunhoffer, Andrew W. Glace, Adam Joseph Freitag, Kathryn Camacho, Francisco González-Bobes, Michael S. Bultman, Victor W. Rosso, Jeanne Ho, Ian S. Young, Albert J. DelMonte, Prantik Maity, Manjunath Gujjar, Gregory L. Beutner, Sunil S. Patel
Publikováno v:
Organic Process Research & Development. 23:2482-2498
The process development and the kilogram-scale synthesis of linrodostat (BMS-986205, 1) are described. The synthesis features several highly efficient telescoped processes and the use of Evans auxi...
Autor:
Jayashree Sahni, Charles C. Wykoff, Dietmar Schwab, Meike Pauly-Evers, Sascha Fauser, Vrinda S. Hershberger, Everson Nogoceke, Arshad M. Khanani, Piotr Szczesny, Sunil S. Patel, Shamil Sadikhov, Aaron Osborne, Chirag Jhaveri, Pravin U. Dugel, Robert James Weikert
Publikováno v:
Ophthalmology. 126:1155-1170
Purpose The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). Des
Autor:
Giovanni Staurenghi, Francisco J. López, Kimmie Kim, Hohman Thomas C, Derek Y Kunimoto, David Callanan, Susan Schneider, Janet K. Cheetham, Sunil S. Patel, Sebastian Wolf, Raj K Maturi
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics
Callanan, David; Kunimoto, Derek; Maturi, Raj K; Patel, Sunil S; Staurenghi, Giovanni; Wolf, Sebastian; Cheetham, Janet K; Hohman, Thomas C; Kim, Kimmie; López, Francisco J; Schneider, Susan (2018). Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. Journal of ocular pharmacology and therapeutics, 34(10), pp. 700-709. Mary Ann Liebert 10.1089/jop.2018.0062
Callanan, David; Kunimoto, Derek; Maturi, Raj K; Patel, Sunil S; Staurenghi, Giovanni; Wolf, Sebastian; Cheetham, Janet K; Hohman, Thomas C; Kim, Kimmie; López, Francisco J; Schneider, Susan (2018). Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration. Journal of ocular pharmacology and therapeutics, 34(10), pp. 700-709. Mary Ann Liebert 10.1089/jop.2018.0062
Purpose: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration. Methods: Phase 2, multicenter, randomized, double-masked